Page last updated: 2024-08-24

imiquimod and sulindac

imiquimod has been researched along with sulindac in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Germain, M; Skelton, H; Smith, KJ1

Other Studies

2 other study(ies) available for imiquimod and sulindac

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2001, Volume: 27, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Carcinoma in Situ; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female; Humans; Imiquimod; Immunosuppression Therapy; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Ointments; Skin Neoplasms; Sulindac

2001